United States Biotechnology & Medical Research

Sutro Biopharma Inc (STRO)

Track

Track

Sutro Biopharma Inc has recorded no insider trading activity within the last three months. The most recent transaction occurred on January 20, 2026, involving a proposed sale by a former officer. Prior to this, several executives executed purchases in October 2025. These historical movements represent the latest documented equity adjustments by company leadership.
Ticker: STRO Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Sutro Biopharma Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
BARBARA LEYMAN Former Officer Officer
Transaction date
Proposed sale
Price
477.48
Quantity 18,053
Value US$247,217
3.3
Gerber Hans-Peter CHIEF SCIENTIFIC OFFICER Officer
Transaction date
Purchase
Price
456.57
Quantity 99,103 +25.0%
Value US$197,865
Pauling David Chief Admin. Ofcr. & GC Officer
Transaction date
Planned purchase
Price
127.79
Quantity 77,841 -20.9%
Value US$851,437
2.7
MATSUI CONNIE Non-Executive Director
Transaction date
Purchase
Price
0.80
Quantity 50,000 +inf%
Value US$39,950
3.6
Chow Gregory K. CFO Officer
Transaction date
Purchase
Price
0.81
Quantity 19,750 +inf%
Value US$15,998
3.3
Chung Jane Chief Executive Officer Executive Director
Transaction date
Purchase
Price
0.80
Quantity 12,500 +11.3%
Value US$10,011
Vasquez Nicki CHIEF PORT. STRAT & ALNCE OFCR Officer
Transaction date
Planned sale
Price
5.00
Quantity 12,185 -48.8%
Value US$60,925
NICKI J VASQUEZ Officer Officer
Transaction date
Proposed sale
Price
5.00
Quantity 12,185
Value US$60,925
3.1
Shtylla Brunilda Chief Business Officer Officer
Transaction date
Planned sale
Price
4.71
Quantity 15,428 -100.0%
Value US$72,595
3.1
Shtylla Brunilda Chief Business Officer Officer
Transaction date
Sale
Price
4.59
Quantity 11,613 -47.3%
Value US$53,282
3.1
Shtylla Brunilda Officer Officer
Transaction date
Proposed sale
Price
5.78
Quantity 27,041
Value US$156,331
3.4
NEWELL WILLIAM J CEO Executive Director
Transaction date
Purchase
Price
7.75
Quantity 10,000 +9.4%
Value US$77,508
Vasquez Nicki Chief Port. Strat & Alnce Ofcr Officer
Transaction date
Planned sale
Price
18.62
Quantity 3,906 -34.9%
Value US$72,724
Hallam Trevor Chief Scientific Officer Officer
Transaction date
Planned sale
Price
26.10
Quantity 165 -0.3%
Value US$4,306
Hallam Trevor Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.68
Quantity 2,228 -3.8%
Value US$57,222
Hallam Trevor Chief Scientific Officer Officer
Transaction date
Planned sale
Price
22.37
Quantity 2,393 -6.1%
Value US$53,530
Hallam Trevor Chief Scientific Officer Officer
Transaction date
Planned sale
Price
17.01
Quantity 2,393 -6.1%
Value US$40,713
Hallam Trevor Chief Scientific Officer Officer
Transaction date
Planned sale
Price
15.00
Quantity 16,751 -31.3%
Value US$251,265
Hallam Trevor Chief Scientific Officer Officer
Transaction date
Planned sale
Price
10.26
Quantity 975 -3.4%
Value US$10,007
2.2
Freund John Gordon Non-Executive Director
Transaction date
Sale
Price
12.00
Quantity 400,000 -41.7%
Value US$4,800,000
2.2
Freund John Gordon Non-Executive Director
Transaction date
Sale
Price
10.00
Quantity 500,000 -34.2%
Value US$5,000,000
Hallam Trevor Chief Scientific Officer Officer
Transaction date
Planned sale
Price
9.04
Quantity 975 -5.5%
Value US$8,818
2.2
Freund John Gordon Non-Executive Director
Transaction date
Sale
Price
8.72
Quantity 500,000 -25.5%
Value US$4,360,000
Hallam Trevor Chief Science Officer Officer
Transaction date
Planned sale
Price
8.06
Quantity 975 -5.2%
Value US$7,858
Hallam Trevor Chief Science Officer Officer
Transaction date
Planned sale
Price
10.00
Quantity 975 -4.7%
Value US$9,753
3.4
NEWELL WILLIAM J CEO Executive Director
Transaction date
Purchase
Price
7.75
Quantity 64,516 +63.2%
Value US$499,999
2.9
MOLINA ARTURO MD Chief Medical Officer Officer
Transaction date
Purchase
Price
7.75
Quantity 6,451 +114.5%
Value US$49,995
3.2
FITZPATRICK LINDA A Chief People & Comm. Officer Officer
Transaction date
Purchase
Price
7.75
Quantity 3,225 +55.8%
Value US$24,994
Hallam Trevor Chief Science Officer Officer
Transaction date
Planned sale
Price
11.19
Quantity 2 -0.0%
Value US$22
Hallam Trevor Chief Science Officer Officer
Transaction date
Planned sale
Price
9.41
Quantity 973 -4.5%
Value US$9,161
Hallam Trevor Chief Science Officer Officer
Transaction date
Planned sale
Price
9.69
Quantity 975 -4.3%
Value US$9,453
Hallam Trevor Chief Science Officer Officer
Transaction date
Planned sale
Price
10.47
Quantity 975 -4.1%
Value US$10,207
Hallam Trevor Chief Science Officer
Transaction date
Planned sale
Price
10.51
Quantity 975 -4.0%
Value US$10,250
Hallam Trevor Chief Science Officer Officer
Transaction date
Planned sale
Price
11.08
Quantity 975 -3.8%
Value US$10,802
Hallam Trevor Chief Science Officer
Transaction date
Planned sale
Price
10.68
Quantity 975 -3.7%
Value US$10,410
Hallam Trevor Chief Science Officer
Transaction date
Planned sale
Price
9.98
Quantity 975 -3.5%
Value US$9,726
Merck & Co., Inc. Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 666,666 +32.4%
Value US$9,999,990
Petree Daniel H Non-Executive Director
Transaction date
Sale
Price
15.00
Quantity 122 -38.9%
Value US$1,830
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-01-20 2026-01-20 PrS Proposed sale
BARBARA LEYMAN

Former Officer

Officer
18,053
477.48
US$247,217 		18,053 477.48 US$247,217
2025-10-16 2025-10-15 B Purchase
3.3
Gerber Hans-Peter

CHIEF SCIENTIFIC OFFICER

Officer
99,103 +25.0%
456.57
US$197,865 		99,103 +25.0% 456.57 US$197,865
2025-10-16 2025-10-15 PP Planned purchase
Pauling David

Chief Admin. Ofcr. & GC

Officer
77,841 -20.9%
127.79
US$851,437 		77,841 -20.9% 127.79 US$851,437
2025-10-16 2025-10-15 B Purchase
2.7
MATSUI CONNIE
Non-Executive Director
50,000 +inf%
0.80
US$39,950 		50,000 +inf% 0.80 US$39,950
2025-10-16 2025-10-15 B Purchase
3.6
Chow Gregory K.

CFO

Officer
19,750 +inf%
0.81
US$15,998 		19,750 +inf% 0.81 US$15,998
2025-10-16 2025-10-15 B Purchase
3.3
Chung Jane

Chief Executive Officer

Executive Director
12,500 +11.3%
0.80
US$10,011 		12,500 +11.3% 0.80 US$10,011
2024-01-31 2024-01-29 PlS Planned sale
Vasquez Nicki

CHIEF PORT. STRAT & ALNCE OFCR

Officer
12,185 -48.8%
5.00
US$60,925 		12,185 -48.8% 5.00 US$60,925
2024-01-29 2024-01-29 PrS Proposed sale
NICKI J VASQUEZ

Officer

Officer
12,185
5.00
US$60,925 		12,185 5.00 US$60,925
2023-08-29 2023-08-28 PlS Planned sale
3.1
Shtylla Brunilda

Chief Business Officer

Officer
15,428 -100.0%
4.71
US$72,595 		15,428 -100.0% 4.71 US$72,595
2023-08-28 2023-08-25 S Sale
3.1
Shtylla Brunilda

Chief Business Officer

Officer
11,613 -47.3%
4.59
US$53,282 		11,613 -47.3% 4.59 US$53,282
2023-08-25 2023-08-25 PrS Proposed sale
3.1
Shtylla Brunilda

Officer

Officer
27,041
5.78
US$156,331 		27,041 5.78 US$156,331
2022-03-15 2022-03-14 B Purchase
3.4
NEWELL WILLIAM J

CEO

Executive Director
10,000 +9.4%
7.75
US$77,508 		10,000 +9.4% 7.75 US$77,508
2021-09-28 2021-09-28 PlS Planned sale
Vasquez Nicki

Chief Port. Strat & Alnce Ofcr

Officer
3,906 -34.9%
18.62
US$72,724 		3,906 -34.9% 18.62 US$72,724
2021-01-27 2021-01-26 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
165 -0.3%
26.10
US$4,306 		165 -0.3% 26.10 US$4,306
2021-01-27 2021-01-26 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
2,228 -3.8%
25.68
US$57,222 		2,228 -3.8% 25.68 US$57,222
2020-12-29 2020-12-28 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
2,393 -6.1%
22.37
US$53,530 		2,393 -6.1% 22.37 US$53,530
2020-11-30 2020-11-27 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
2,393 -6.1%
17.01
US$40,713 		2,393 -6.1% 17.01 US$40,713
2020-11-06 2020-11-05 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
16,751 -31.3%
15.00
US$251,265 		16,751 -31.3% 15.00 US$251,265
2020-09-28 2020-09-28 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
975 -3.4%
10.26
US$10,007 		975 -3.4% 10.26 US$10,007
2020-09-22 2020-09-18 S Sale
2.2
Freund John Gordon
Non-Executive Director
400,000 -41.7%
12.00
US$4,800,000 		400,000 -41.7% 12.00 US$4,800,000
2020-09-15 2020-09-11 S Sale
2.2
Freund John Gordon
Non-Executive Director
500,000 -34.2%
10.00
US$5,000,000 		500,000 -34.2% 10.00 US$5,000,000
2020-08-27 2020-08-26 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
975 -5.5%
9.04
US$8,818 		975 -5.5% 9.04 US$8,818
2020-08-21 2020-08-19 S Sale
2.2
Freund John Gordon
Non-Executive Director
500,000 -25.5%
8.72
US$4,360,000 		500,000 -25.5% 8.72 US$4,360,000
2020-07-28 2020-07-27 PlS Planned sale
Hallam Trevor

Chief Science Officer

Officer
975 -5.2%
8.06
US$7,858 		975 -5.2% 8.06 US$7,858
2020-05-27 2020-05-26 PlS Planned sale
Hallam Trevor

Chief Science Officer

Officer
975 -4.7%
10.00
US$9,753 		975 -4.7% 10.00 US$9,753
2020-05-14 2020-05-14 B Purchase
3.4
NEWELL WILLIAM J

CEO

Executive Director
64,516 +63.2%
7.75
US$499,999 		64,516 +63.2% 7.75 US$499,999
2020-05-14 2020-05-14 B Purchase
2.9
MOLINA ARTURO MD

Chief Medical Officer

Officer
6,451 +114.5%
7.75
US$49,995 		6,451 +114.5% 7.75 US$49,995
2020-05-14 2020-05-14 B Purchase
3.2
FITZPATRICK LINDA A

Chief People & Comm. Officer

Officer
3,225 +55.8%
7.75
US$24,994 		3,225 +55.8% 7.75 US$24,994
2020-04-27 2020-04-27 PlS Planned sale
Hallam Trevor

Chief Science Officer

Officer
2 -0.0%
11.19
US$22 		2 -0.0% 11.19 US$22
2020-04-27 2020-04-27 PlS Planned sale
Hallam Trevor

Chief Science Officer

Officer
973 -4.5%
9.41
US$9,161 		973 -4.5% 9.41 US$9,161
2020-03-27 2020-03-26 PlS Planned sale
Hallam Trevor

Chief Science Officer

Officer
975 -4.3%
9.69
US$9,453 		975 -4.3% 9.69 US$9,453
2020-02-27 2020-02-26 PlS Planned sale
Hallam Trevor

Chief Science Officer

Officer
975 -4.1%
10.47
US$10,207 		975 -4.1% 10.47 US$10,207
2020-01-28 2020-01-27 PlS Planned sale
Hallam Trevor

Chief Science Officer
975 -4.0%
10.51
US$10,250 		975 -4.0% 10.51 US$10,250
2019-12-27 2019-12-26 PlS Planned sale Hallam Trevor

Chief Science Officer

Officer
975 -3.8%
11.08
US$10,802 		975 -3.8% 11.08 US$10,802
2019-11-27 2019-11-26 PlS Planned sale
Hallam Trevor

Chief Science Officer
975 -3.7%
10.68
US$10,410 		975 -3.7% 10.68 US$10,410
2019-10-30 2019-10-28 PlS Planned sale
Hallam Trevor

Chief Science Officer
975 -3.5%
9.98
US$9,726 		975 -3.5% 9.98 US$9,726
2018-10-02 2018-10-01 B Purchase Merck & Co., Inc. Large shareholder
666,666 +32.4%
15.00
US$9,999,990 		666,666 +32.4% 15.00 US$9,999,990
2018-10-01 2018-10-01 S Sale Petree Daniel H Non-Executive Director
122 -38.9%
15.00
US$1,830 		122 -38.9% 15.00 US$1,830
Explore more

More insider trading research around Sutro Biopharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America